[go: up one dir, main page]

BR0303012A - Avaliação de câncer colorretal - Google Patents

Avaliação de câncer colorretal

Info

Publication number
BR0303012A
BR0303012A BR0303012-1A BR0303012A BR0303012A BR 0303012 A BR0303012 A BR 0303012A BR 0303012 A BR0303012 A BR 0303012A BR 0303012 A BR0303012 A BR 0303012A
Authority
BR
Brazil
Prior art keywords
colorectal cancer
cancer assessment
cancer
assessment
colorretal
Prior art date
Application number
BR0303012-1A
Other languages
English (en)
Inventor
Yixin Wang
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BR0303012A publication Critical patent/BR0303012A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"AVALIAçãO DE CâNCER COLORRETAL". Um método para avaliar a presença ou ausência de câncer colorretal ou a condição provável de uma pessoa que se acredita que tenha câncer colorretal é conduzido analisando a expressão de um grupo de genes. Perfis de expressão genética em uma variedade de meios tais como micro-séries são incluídos bem como kits que contêm os mesmos.
BR0303012-1A 2002-03-29 2003-03-28 Avaliação de câncer colorretal BR0303012A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36868702P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
BR0303012A true BR0303012A (pt) 2004-09-08

Family

ID=28675528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0303012-1A BR0303012A (pt) 2002-03-29 2003-03-28 Avaliação de câncer colorretal

Country Status (10)

Country Link
US (1) US20030186303A1 (pt)
EP (1) EP1355151A3 (pt)
JP (2) JP4354725B2 (pt)
KR (1) KR100984996B1 (pt)
CN (2) CN1502989A (pt)
AR (1) AR039211A1 (pt)
AU (1) AU2003203561A1 (pt)
BR (1) BR0303012A (pt)
CA (1) CA2422305C (pt)
MX (1) MXPA03002863A (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20050153352A1 (en) * 2004-01-09 2005-07-14 Stanley Chang Cancer specific gene MG20
EP1871163A2 (en) * 2005-06-06 2008-01-02 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US8249814B2 (en) * 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
EP1996729A2 (en) * 2006-03-03 2008-12-03 Veridex, LLC Molecular assay to predict recurrence of dukes' b colon cancer
RU2565540C2 (ru) * 2007-10-23 2015-10-20 Клиникал Джиномикс Пти. Лтд. Способ диагностики неоплазм-ii
EP2169078A1 (en) 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
WO2013092960A1 (en) 2011-12-22 2013-06-27 Fundacion Gaiker Methods and kits for the diagnosis of colorectal cancer
CN102586423B (zh) * 2011-12-27 2015-01-07 盛司潼 一种检测结直肠癌易感基因的方法及试剂盒
CN102586420B (zh) * 2011-12-27 2014-10-22 盛司潼 一种检测乳腺癌易感基因的方法及试剂盒
CN115678994B (zh) * 2022-01-27 2025-01-21 上海爱谱蒂康生物科技有限公司 一种生物标志物组合、含其的试剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US635152A (en) * 1899-06-05 1899-10-17 Melancthon S Shotwell Car-body bolster.
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6350578B1 (en) * 1999-06-25 2002-02-26 The Regents Of The University Of California Method of quantitating dsDNA
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators

Also Published As

Publication number Publication date
JP2003325191A (ja) 2003-11-18
CN1502989A (zh) 2004-06-09
AR039211A1 (es) 2005-02-09
CA2422305A1 (en) 2003-09-29
US20030186303A1 (en) 2003-10-02
EP1355151A3 (en) 2004-08-25
KR20030078801A (ko) 2003-10-08
MXPA03002863A (es) 2004-08-11
JP2009153521A (ja) 2009-07-16
JP4354725B2 (ja) 2009-10-28
KR100984996B1 (ko) 2010-10-04
CN101684500A (zh) 2010-03-31
CA2422305C (en) 2013-07-30
EP1355151A2 (en) 2003-10-22
AU2003203561A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
BRPI0403169A (pt) Prognósticos de câncer colorretal
BRPI0603053A (pt) previsão de reicidiva de osso de cáncer de mama
BR0303012A (pt) Avaliação de câncer colorretal
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
PL393466A1 (pl) Sposób stymulacji biogenicznego wytwarzania metanu z formacji węglowodoronośnych
WO2009009752A3 (en) Genetic models for stratification of cancer risk
BR0303091A (pt) Avaliação de câncer colorretal
ATE381552T1 (de) Derivate von 1-piperazin- und 1- homopiperazincarboxylaten, verfahren zu deren herstellung und deren verwendung als inhibitoren des faah-enzyms
ATE522627T1 (de) Verfahren zur herstellung von nukleinsäuresonden
Mahon et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study
Ma et al. Expression profiles analysis of long non-coding RNAs identified novel lncRNA biomarkers with predictive value in outcome of cutaneous melanoma
AR044099A1 (es) Pronostico de cancer de mama
BRPI0403812A (pt) Prognósticos de câncer coloretal
DE60009530D1 (de) Genetische toxizitätsmarker, herstellung und verwendung
DK1766088T3 (da) Identificering af kromosomabnormaliteter i celler, der opnået fra follikelvæske
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
ATE466958T1 (de) Klassifizierung von kolonkrebs
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
WO2004035805A3 (en) Differential patterns of gene expression that predict for docetaxel chemosensitivity and chemoresistance
ATE445592T1 (de) Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren
WO2004097005A3 (en) Global analysis of transposable elements as molecular markers of the developmental potential of stem cells
Ohnmacht et al. The pharmacogenomic assessment of molecular epithelial-mesenchymal transition signatures reveals drug susceptibilities in cancer cell lines
WO2008061525A3 (de) Prognostische marker für die klassifizierung des dreijährigen progressionsfreien überlebens von patienten mit kolorektalem karzinom basierend auf expressionsprofilen von biologischen proben
BRPI0507392A (pt) método e kit para determinar a possibilidade de metástase de cáncer em um indivìduo
Reardon et al. 12. Expanding clinical actionability in individual patient profiles with the Molecular Oncology Almanac

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]